CastleVax is the proven technology that will bring safe vaccines for all humans, everywhere. Our state-of-the-art platform for producing first-in-class vaccines uses Newcastle Disease Virus (NDV) to enable rapid development of safe and highly immunogenic viral vectors that are easy to deliver and store, and can be administered via injection or intranasally.
CastleVax的外部链接
Great article by Stephani Sutherland in Scientific American, featuring quotes from our CEO, Michael Egan! #COVID #VaccineDevelopment #Innovation #PublicHealth #CastleVax
Gentle nasal spray vaccines against COVID, the flu and RSV are coming. They may work better than shots in the arm https://trib.al/HA7REl9
We are pleased to share that we are the grateful recipients of a Biomedical Advanced Research and Development Authority (BARDA) Project NextGen?award, valued at approximately $34 million, to support the continued development of our next-generation mucosal COVID-19 vaccine. https://lnkd.in/ejr9sE9F #vaccinedevelopment #projectnextgen #covid19 #castlevax #BARDA
We had a great time at the #BLUEKNIGHT2024 Symposium! Thanks to everyone involved for making it such a fantastic event. Looking forward to staying connected and collaborating in the future! ?? #BIO2024 #healthcareinnovation #CastleVax #collaboration #vaccinedevelopment
Our Director of Operations extraordinaire, Jori Horberg, represented CastleVax with distinction in this panel last week! We're proud to have her on our team ??
It was a terrific week in New York City last week, including a panel discussion at #JLABS #NYC highlighting some of the recent major milestones of two #BLUEKNIGHT companies. Both mPOD, Inc. and CastleVax have been successfully navigating the NYC ecosystem since launching at a New York City Health Hackathon (mPOD) and spinning out of Mount Sinai Health System (CastleVax). In the last few months, both companies have reached critical inflection points from initiating and enrolling clinical studies, to regulatory milestones, and receiving non-dilutive funding awards. Thank you, Jeffrey Ly and Jori Horberg, for sharing your lessons learned and Ashim Subedee for highlighting opportunities for engaging with the Biomedical Advanced Research and Development Authority (BARDA), including through Blue Knight, the joint initiative with JLABS. Tingting Zhang-Kharas, PhD, and the entire JLABS @ NYC team, thank you for your support of the early-stage companies in the region and for hosting this engaging discussion! Be sure to subscribe here to make sure you're hearing updates on the progress of Blue Knight companies: https://lnkd.in/eqHuhpE3 Tatiana Canessa Jesse Hwang Courtney Delatorre, PMP Tracy Barbot, MBA Michael Egan
Sharing some highlights from our team's experience at The World Vaccine Congress this week! The team enjoyed the insightful discussions and networking opportunities, and our fearless leader Michael Egan was a featured speaker in two events: ??Day 1 | Start-up Pitch: Leveraging the innovative NDV-vector platform to develop vaccines targeting pathogens with substantial unmet need ??Day 3 | Panel: How Can We Leverage and Secure US Government R&D Funding from Domestic Agencies (HHS, DoD, etc.) to Spur Vaccine Development and Better Distribution? #WVCUSA?#WVC2024 #networking #startup #vaccinedevelopment #vaccinenation
CastleVax转发了
With just days to The World Vaccine Congress #wvcdc we're excited to share a #successtory: the partnership between Jurata Thin Film and CastleVax. In this post we hear from Dr Michael Egan and Ms. Megan Livingston how their initial meeting in the #startup zone led them to identify "alignment" in "intents and interests" as well as approaches. They are now working with Johnson & Johnson #BLUEKNIGHT and have seen positive developments in their work already. Read the article to hear more about their partnership, and make sure you introduce yourself to your neighbours at the event next week! This is a fantastic example of the opportunities that Isabella Aung's #startups take, and we hope to hear more from this year! #vaccinenation #vaccine #innovation #jlabs
Exciting News in the Fight Against COVID-19!? We are thrilled to share that?our partners at?Thailand’s The Government Pharmaceutical Organization (GPO) have received conditional approval for emergency use of its NDV-HXP-S COVID-19 vaccine. This marks a significant milestone as it is the first domestically produced COVID-19 vaccine in Thailand. What sets this?vaccine apart is its potential to be an affordable option that advances vaccine supply sustainability and pandemic preparedness. The Icahn School of Medicine at Mount Sinai in New York and The The University of Texas at Austin played crucial roles in developing the vaccine technology, making it a testament to global collaboration in the fight against COVID-19. Congratulations to GPO and Thailand on achieving this milestone, and?a?shoutout to PATH for their support in this journey. This locally produced COVID-19 booster option not only protects Thailand's population but also paves the way for other egg-based vaccine manufacturers globally. It's?real-world?proof that the Newcastle Disease Virus vaccine platform?can be leveraged to produce innovative vaccines?with broad public health potential. #covid19 #vaccinedevelopment #covid19response #CastleVax #milestone ? https://lnkd.in/eYDYXtu9
We are proud to share our CEO/CSO Michael Egan will be speaking in a fireside chat at The World Vaccine Congress this week! ???? Dr. Egan will share insights on how we've accelerated our technology by leveraging opportunities such as state-level funding and a Biomedical Advanced Research and Development Authority (BARDA) #BlueKnight #JLabs #ProjectNextGen incubation award.